Investor Center
EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMed’s drug candidates target disease cells and the blood vessels that nourish them. The company’s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell signaling, cell cycle regulation and inflammation—processes that are vital to the progression of cancer and other diseases.
2009 10-K, Annual Meeting Notice and Proxy Statement
Reverse Split FAQs [PDF]
Upcoming Events
There are no upcoming events at this time.
Webcasts and Presentations
Stockholders' Meeting Presentation
June 3, 2010
June 3, 2010
Conference Call
May 18, 2010
EntreMed Provides Corporate Update and Reports First Quarter 2010 Financial Results
To access the recording, dial 800-642-1687 (U.S. or Canada) or 706-645-9291 (internationally) and enter the Conference ID number 73228525
May 18, 2010
EntreMed Provides Corporate Update and Reports First Quarter 2010 Financial Results
To access the recording, dial 800-642-1687 (U.S. or Canada) or 706-645-9291 (internationally) and enter the Conference ID number 73228525
Listen to a recording of the May 18, 2010 call:
10-K Downloads
2004, 2005, 2006, 2007, 2008, 2009
SEC Filings
View all SEC filings, View only Section 16 SEC filings
Please note that the above are links to www.sec.gov, a third-party web site. EntreMed, Inc. does not maintain nor provide any information directly to www.sec.gov, and therefore makes no representations or warranties regarding the the information contained therein. Further, EntreMed takes no responsibility for supplementing, updating, or correcting any information found on www.sec.gov.
Corporate Governance Documents
Code of Ethics, Audit Committee Charter, Compensation Committee Charter, Nominating and Corporate Governance Committee Charter
Safe Harbor Information
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to our ability to obtain additional financing; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of Panzem®; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
